S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Abbott Laboratories Outlook is Healthy: Buy the Dip
Closing prices for crude oil, gold and other commodities
Stock market today: World shares are mixed after a tech-led retreat on Wall Street
Prologis Stock Leading U.S. Logistics Boom
Johnson & Johnson’s Q1 Checkup: Mixed Results, Optimism Remains
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Abbott Laboratories Outlook is Healthy: Buy the Dip
Closing prices for crude oil, gold and other commodities
Stock market today: World shares are mixed after a tech-led retreat on Wall Street
Prologis Stock Leading U.S. Logistics Boom
Johnson & Johnson’s Q1 Checkup: Mixed Results, Optimism Remains
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Abbott Laboratories Outlook is Healthy: Buy the Dip
Closing prices for crude oil, gold and other commodities
Stock market today: World shares are mixed after a tech-led retreat on Wall Street
Prologis Stock Leading U.S. Logistics Boom
Johnson & Johnson’s Q1 Checkup: Mixed Results, Optimism Remains
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Abbott Laboratories Outlook is Healthy: Buy the Dip
Closing prices for crude oil, gold and other commodities
Stock market today: World shares are mixed after a tech-led retreat on Wall Street
Prologis Stock Leading U.S. Logistics Boom
Johnson & Johnson’s Q1 Checkup: Mixed Results, Optimism Remains

Finch Therapeutics Group (FNCH) Earnings Date, Estimates & Call Transcripts

$2.52
-0.58 (-18.71%)
(As of 04/17/2024 ET)

Earnings Summary

Upcoming
Earnings Date
May. 8Estimated
Actual EPS
(Mar. 25)
-$1.89 Missed By -$1.89
Skip Charts & View Estimated and Actual Earnings Data

FNCH Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

FNCH Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

FNCH Earnings Date and Information

Finch Therapeutics Group last announced its quarterly earnings results on March 25th, 2024. The reported ($1.89) earnings per share for the quarter. Finch Therapeutics Group has generated ($47.67) earnings per share over the last year (($47.67) diluted earnings per share). Finch Therapeutics Group has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, May 8th, 2024 based off prior year's report dates.

Finch Therapeutics Group Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
5/8/2024
Estimated)
------- 
3/25/2024Q4 2023-($1.89)($1.89)($1.89)--
11/8/2023Q3 2023-($1.51)($1.51)($1.51)--
8/10/2023Q2 2023($4.51)($4.33)+$0.18($4.33)--
5/10/2023Q1 2023($2.70)($15.60)($12.90)$0.29-$0.11 million
3/23/2023Q4 2022($11.70)($16.80)($5.10)($0.56)$0.40 million$0.01 million
11/10/2022Q3 2022($12.00)($13.50)($1.50)($0.05)$1.50 million$0.14 million
8/11/2022Q2 2022($13.80)($14.40)($0.60)($0.48)-$0.36 million
5/16/2022Q1 2022-($15.60)($15.60)($0.52)-$0.35 million
3/31/2022Q4 2021($12.60)($12.00)+$0.60($0.40)$5.00 million$0.81 million
11/10/2021Q3 2021($12.60)($6.30)+$6.30($0.21)-$11.34 million
8/10/2021Q2 2021($8.40)($9.60)($1.20)($0.32)-$2.83 million
5/13/2021Q1 2021($6.90)($30.00)($23.10)($1.00)-$3.55 million

Finch Therapeutics Group Earnings - Frequently Asked Questions

When is Finch Therapeutics Group's earnings date?

Finch Therapeutics Group has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, May 8th, 2024 based off last year's report dates. Learn more on FNCH's earnings history.

How much revenue does Finch Therapeutics Group generate each year?

Finch Therapeutics Group (NASDAQ:FNCH) has a recorded annual revenue of $110,000.00.

How much profit does Finch Therapeutics Group generate each year?

Finch Therapeutics Group (NASDAQ:FNCH) has a recorded net income of -$74.75 million. FNCH has generated -$47.67 earnings per share over the last four quarters.


More Earnings Resources from MarketBeat

This page (NASDAQ:FNCH) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners